Flortaucipir patterns in preclinical Alzheimer’s disease: an evaluation of TRAILBLAZER‐ALZ 3 baseline data

Abstract

Background: Preclinical Alzheimer’s disease (AD) populations have evidence of elevated brain amyloid but are cognitively unimpaired. Most participants (95%) in solanezumab’s preclinical AD trial, Anti‐Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4), did not demonstrate elevated global tau accumulation at baseline.